Lee Yun-Hee, Kim Ji-Yoon, Choi Byung-Ock, Ryu Mi-Ryeong, Chung Su-Mi
Department of Radiation Oncology, The Catholic University of Korea College of Medicine, Seoul, Korea.
Radiat Oncol J. 2012 Dec;30(4):165-72. doi: 10.3857/roj.2012.30.4.165. Epub 2012 Dec 31.
To retrospectively evaluate the outcome and toxicity of total lymphoid irradiation (TLI) based conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in severe aplastic anemia (SAA) patients who experienced an engraftment failure from prior HSCT or were heavily transfused.
Between 1995 and 2006, 20 SAA patients received TLI for conditioning of HSCT. All patients were multi-transfused or had long duration of disease. Fifteen (75%) patients had graft failure from prior HSCT. In 18 (90%) patients, the donors were human leukocyte antigen identical siblings. The stem cell source was the peripheral blood stem cell in 15 (75%) patients. The conditioning regimen was composed of antithymocyte globulin plus TLI with a median dose of 750 cGy in 1 fraction. The graft-versus-host disease (GVHD) prophylaxis used cyclosporine with methotrexate.
With a median follow-up of 10.8 years, graft failures developed in 6 patients. Among them, 3 patients received their third HSCT to be engrafted finally. The Kaplan-Meier overall survival rate was 85.0% and 83.1% at 5 and 10 years, respectively. The incidence of acute and chronic GVHD was 20% and 20%, respectively. None of the patients have developed a malignancy after HSCT.
In our study, TLI based conditioning in allogeneic HSCT was feasible with acceptable rates of GVHD in SAA patients who experienced graft failure from prior HSCT or was at a high risk of graft rejection. We achieved relatively better results of engraftment and survival with a long term follow-up.
回顾性评估基于全身淋巴照射(TLI)的预处理方案用于异基因造血干细胞移植(HSCT)治疗严重再生障碍性贫血(SAA)患者的疗效及毒性,这些患者既往HSCT发生植入失败或接受过大量输血。
1995年至2006年期间,20例SAA患者接受TLI进行HSCT预处理。所有患者均多次输血或病程较长。15例(75%)患者既往HSCT发生移植失败。18例(90%)患者的供者为人类白细胞抗原相合的同胞。15例(75%)患者的干细胞来源为外周血干细胞。预处理方案由抗胸腺细胞球蛋白加TLI组成,中位剂量为750 cGy,单次照射。移植物抗宿主病(GVHD)预防采用环孢素联合甲氨蝶呤。
中位随访10.8年,6例患者发生移植失败。其中,3例患者接受了第三次HSCT最终实现植入。Kaplan-Meier法计算的5年和10年总生存率分别为85.0%和83.1%。急性和慢性GVHD的发生率分别为20%和20%。HSCT后无患者发生恶性肿瘤。
在我们的研究中,对于既往HSCT发生移植失败或有高移植排斥风险的SAA患者,基于TLI的异基因HSCT预处理是可行的,GVHD发生率可接受。长期随访显示,我们在植入和生存方面取得了相对较好的结果。